Clinical Trials Logo

Corneal Dystrophies, Hereditary clinical trials

View clinical trials related to Corneal Dystrophies, Hereditary.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05376176 Active, not recruiting - Clinical trials for Fuchs Endothelial Corneal Dystrophy

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)

PHANTOM
Start date: May 19, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase IIa study to assess efficacy and safety of STN1010904 ophthalmic suspension (0.03%, and 0.1 %), twice daily dosing when compared to Placebo in subjects diagnosed with Fuchs Endothelial Corneal Dystrophy (FECD). This study will consist of a Screening Period of up to 15 days and an 18-month Double-Masked Treatment Period, including 9 individual visits to the study site.

NCT ID: NCT04894110 Active, not recruiting - Clinical trials for Endothelial Dysfunction

Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema

Start date: June 22, 2021
Phase: Phase 1
Study type: Interventional

Corneal edema is the most common indication for corneal transplantation, accounting for approximately 70% of penetrating keratoplasty (PK), and 100% of endothelial keratoplasty (EK) procedures annually. There is currently no disease-modifying treatment for corneal edema. Topical treatments like hypertonic saline are not effective on a long-term basis. For those with advanced disease, where edema and vision loss are not controlled by topical treatment, the only option is a corneal transplant. A potential approach to avoidance of the risks of corneal transplantation is to inject cultured human corneal endothelial cells (HCECs) into the anterior chamber of the eye. This approach may avoid surgery by re-populating the inner most aspect of the cornea with functioning endothelial cells. Emmecell has developed a treatment based on technology integrating biocompatible magnetic nanoparticles with cultured HCECs to treat corneal edema in a minimally invasive way. The primary objective of this phase 1, prospective, multi-center, open-label, dose-escalation study is to evaluate the safety and tolerability of 3 doses of EO2002 with and without endothelial brushing (EB) or Descemet Stripping (DS) in eyes with corneal edema secondary to corneal endothelial dysfunction that qualify for surgery involving full-thickness corneal transplantation or EK.

NCT ID: NCT04667572 Active, not recruiting - Keratoconus Clinical Trials

Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

Start date: February 1, 2021
Phase: Phase 1
Study type: Interventional

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in Eyes With Corneal Thinning Conditions

NCT ID: NCT04564378 Active, not recruiting - Fuchs Dystrophy Clinical Trials

Association Between Fuchs' Endothelial Corneal Dystrophy Severity and Estrogen Exposure

Start date: January 17, 2018
Phase:
Study type: Observational

This study is being done to discover if there is a link between estrogen exposure and the severity of Fuchs Endothelial Corneal Disease. We are trying to understand if the decrease in estrogen levels in post-menopausal women may be a reason why FECD is seen more often in women than men.